BUZZ-Solid Biosciences jumps on early-stage data from gene therapy

Shares of Solid Biosciences SLDB.O rises 51.9% to $6.12

Co says its experimental gene therapy for a rare muscle wasting disorder was well-tolerated in 6 participants dosed in an early-stage study

Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which interferes with the production of proteins needed to form healthy muscles

Says no serious adverse events were observed

Also says that some patients showed significant improvements in multiple muscle health biomarkers

Separately, co's 35.7 mln stock offering priced at $4.03 each, which was the last closing price of its shares

SLDB has fallen ~56% in the last 12 months